United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

modern pharmaceutical company united kingdom - 1 mobile application software - software - software - medical devices-medical devices

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

modern pharmaceutical company united states of america - 1 mobile application software mmt-8201 (android) - software - software - n/a

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmatrade germany - 1 software application [pwd (08758905) & hcp (08888353)] - software - application software - medical devices-medical devices

Kenya - English - Pharmacy and Poisons Board

galaxy pharmaceutical limited p.o. box 39107-00623, nairobi - each soft gelatin capsule contains… - capsule, soft - each soft gelatin capsule contains… - other antiepileptics

Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 200 mg - capsule, soft - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - prometrium 100 mg and 200 mg, soft capsules are indicated for:,treatment of menstrual irregularities,- in women with menstrual abnormalities or secondary amenorrhoea due to normogonadotrophic amenorrhoea (see dosage and administration),hormone replacement therapy,- hormone replacement therapy ? adjunctive use with an oestrogen in postmenopausal women with an intact uterus

Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 100 mg - capsule, soft - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - prometrium 100 mg and 200 mg, soft capsules are indicated for:,treatment of menstrual irregularities,- in women with menstrual abnormalities or secondary amenorrhoea due to normogonadotrophic amenorrhoea (see dosage and administration),hormone replacement therapy,- hormone replacement therapy ? adjunctive use with an oestrogen in postmenopausal women with an intact uterus

Malta - English - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - dutasteride - soft capsule - dutasteride 0.5 mg - urologicals

Philippines - English - FDA (Food And Drug Administration)

sahar international trading, inc.; distributor: sahar international trading, inc. - phospholipids , multivitamins - softgel capsule - each softgel capsule contains: 3 sn phosphatidylcholine (phospholipids) 300 mg rrr-alpha-tocopheryl acetate (vitamin e) 6 mg thiamine mononitrate (vitamin b1) 6 mg riboflavin (vitamin b2) 6 mg nicotinamide (vitamin b3) 30 mg pyridoxine hydrochloride (vitamin b6) 6 mg cyanocobalamin (vitamin b12) 6 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nintedanib esilate, quantity: 180.6 mg (equivalent: nintedanib, qty 150 mg) - capsule, soft - excipient ingredients: iron oxide red; titanium dioxide; hard fat; lecithin; gelatin; glycerol; iron oxide yellow; medium chain triglycerides; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - ofev is indicated in combination with docetaxel for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (nsclc) of adenocarcinoma tumour histology after failure of first line chemotherapy.,ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf).,ofev is also indicated for the treatment of other chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype.,ofev is indicated for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nintedanib esilate, quantity: 120.4 mg (equivalent: nintedanib, qty 100 mg) - capsule, soft - excipient ingredients: hard fat; lecithin; glycerol; iron oxide red; gelatin; medium chain triglycerides; titanium dioxide; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - ofev is indicated in combination with docetaxel for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (nsclc) of adenocarcinoma tumour histology after failure of first line chemotherapy.,ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf).,ofev is also indicated for the treatment of other chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype.,ofev is indicated for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild).